Plain-English translation of NCT05408221 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a combination of two medications—rulonilimab and lenvatinib—to see if they work better together than lenvatinib by itself for treating advanced liver cancer. Rulonilimab is a new drug that works by helping your immune system fight cancer cells. Half of the participants will receive the new combination, and half will receive lenvatinib with a placebo (a fake medication), so researchers can fairly compare how well the treatment works.
Advanced liver cancer is hard to treat, and current single-drug treatments don't work well enough for many patients. This trial is testing whether combining this new immune-boosting medication with an existing cancer drug can help more patients live longer and healthier lives.
This trial has two phases. In the first phase, a small group of participants will receive the new combination medication to check that it is safe and tolerable. In the second phase, a larger group of participants will be randomly assigned to either receive the new combination or lenvatinib with a placebo. You will need to visit the clinic regularly for blood tests, imaging scans, and check-ups with your doctor to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China